"Matching" the "Mismatch" Repair-Deficient Prostate Cancer with Immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31900277.
- Also identified by DOI 10.1158/1078-0432.CCR-19-3780 and PMC identifier 7123990.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mismatch repair gene mutations are uncommon in advanced prostate cancer; however, in those harboring these alterations, immune checkpoint blockade can be effective. As such, assays that can accurately identify these men are critically important. Cell-free circulating tumor DNA-based sequencing approaches appear to be one viable approach for identifying these patients.<i>See related article by Ritch et al., p. 1114</i>.
Medical subject headings
- Circulating Tumor DNA
- Prostatic Neoplasms